AB Science obtains a patent in China for masitinib against COVID-19

AB Science SA announced that it has been granted a patent in China for masitinib, protecting its use in the treatment of COVID-19 until 2041. This patent strengthens the intellectual property rights surrounding this molecule in this indication. The collaboration agreement with the University of Chicago provides AB Science with an exclusive license in the event of commercialization of the discovered viral treatments.

Preclinical studies have shown that masitinib acts as a broad-spectrum antiviral agent, effective against SARS-CoV-2 and its variants. Results from the Phase 2 study revealed anti-inflammatory properties of masitinib, suggesting its potential as a treatment in a future pandemic situation.